Nam Hee Kim

6551774, Apr 22, 2003

Aug 20, 1999

09/378535

Michael D. West - San Carlos CA
Calvin B. Harley - Palo Alto CA
Scott L. Weinrich - San Francisco CA
Catherine M. Strahl - San Francisco CA
Michael J. McEachern - San Francisco CA
Jerry Shay - Dallas TX
Woodring E. Wright - Arlington TX
Elizabeth H. Blackburn - San Francisco CA
Nam Woo Kim - Sunnyvale CA
Homayoun Vaziri - Toronto, CA

Board of Regents, The University of Texas System - Dallas TX
The Regents of the University of California - Oakland CA
Geron Corporation - Menlo Park CA

C12Q 168

435 6, 435 71, 435 15, 435 912, 435 915

Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.

7294704, Nov 13, 2007

Aug 16, 2004

10/919215

Iris Simon - San Franscisco CA, US
Laura Corral - San Francisco CA, US
Charis Lawrenson - San Jose CA, US
Nam Kim - Santa Clara CA, US
Glenn Pilkington - Sorrento, AU
Robert L. Wolfert - Palo Alto CA, US

diaDexus, Inc. - South San Francisco CA

C07K 16/00

5303881, 5303871, 5303873, 53038815, 4241411

This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies.

7500032, Mar 3, 2009

Aug 31, 2007

11/848758

Ook Kim - Palo Alto CA, US
Eric Lee - San Jose CA, US
Gyudong Kim - Sunnyvale CA, US
Baegin Sung - Sunnyvale CA, US
Nam Hoon Kim - Cupertino CA, US
Gijung Ahn - San Jose CA, US
Seung Ho Hwang - Palo Alto CA, US

Silicon Image, Inc - Sunnyvale CA

G06F 13/38

710 72

A cable including circuitry for asserting information to a user or external device and a system including such a cable. The cable can include conductors, a memory storing cable data, and circuitry configured to respond to a request received on at least one of the conductors by accessing at least some of the cable data and asserting the accessed data serially to at least one of the conductors (e. g. , for transmission to an external device). Other aspects of the invention are methods for accessing cable data stored in a cable and optionally using the data (e. g. , to implement equalization). The cable data can be indicative of all or some of cable type, grade, speed, length, and impedance, a date code, a frequency-dependent attenuation table, far-end crosstalk and EMI-related coefficients, common mode radiation, intra pair skew, and other information. The cable can include a radiation-emitting element and circuitry for generating driving signals for causing the radiation-emitting element to produce an appropriate color, brightness, and/or blinking pattern.

7560531, Jul 14, 2009

Jun 1, 2004

10/558543

Xiaozhu Duan - Alameda CA, US
Nam Kim - Santa Clara CA, US
Robert L. Wolfert - Palo Alto CA, US

diaDexus, Inc. - South San Francisco CA

A61K 38/48

5303871

This invention relates to a method for assessing risk of prostate and/or ovarian cancer. Specifically, in one embodiment it relates to utilizing both Cln101 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In an alternative embodiment, the invention is relates to utilizing Cln101 alone or in combination with CA125 to determine the risk of ovarian cancer. The invention further provides isolated anti-prostate or ovarian cancer antigen (Cln101) antibodies that bind to Cln101 in vivo. The invention also encompasses compositions comprising an anti-Cln101 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Cln101 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Cln101 antibodies. The invention encompasses a method of producing the anti-Cln10I antibodies.

8148093, Apr 3, 2012

Oct 3, 2007

11/866475

Iris Simon - San Francisco CA, US
Laura Corral - San Francisco CA, US
Charis Lawrenson - San Jose CA, US
Nam Kim - Santa Clara CA, US
Glenn Pilkington - Sorrento, AU
Robert L. Wolfert - Palo Alto CA, US

diaDexus, Inc. - South San Francisco

G01N 33/53
G01N 33/574
G01N 33/60

435 723, 435 71, 435 72, 435 721, 435 76, 436501, 436503, 436504, 436 63, 436 64

This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies.

7269673, Sep 11, 2007

Feb 18, 2004

10/781405

Ook Kim - Palo Alto CA, US
Eric Lee - San Jose CA, US
Gyudong Kim - Sunnyvale CA, US
Baegin Sung - Sunnyvale CA, US
Nam Hoon Kim - Cupertino CA, US
Gijung Ahn - San Jose CA, US
Seung Ho Hwang - Palo Alto CA, US

Silicon Image, Inc. - Sunnyvale CA

G06F 13/38

710 72

A cable including circuitry for asserting information to a user or external device and a system including such a cable. The cable can include conductors, a memory storing cable data, and circuitry configured to respond to a request received on at least one of the conductors by accessing at least some of the cable data and asserting the accessed data serially to at least one of the conductors (e. g. , for transmission to an external device). Other aspects of the invention are methods for accessing cable data stored in a cable and optionally using the data (e. g. , to implement equalization). The cable data can be indicative of all or some of cable type, grade, speed, length, and impedance, a date code, a frequency-dependent attenuation table, far-end crosstalk and EMI-related coefficients, common mode radiation, intra pair skew, and other information. The cable can include a radiation-emitting element and circuitry for generating driving signals for causing the radiation-emitting element to produce an appropriate color, brightness, and/or blinking pattern.

20030190638, Oct 9, 2003

Aug 29, 2002

10/232927

Michael West - San Carlos CA, US
Calvin Harley - Palo Alto CA, US
Scott Weinrich - San Francisco CA, US
Catherine Strahl - San Francisco CA, US
Michael McEachern - San Francisco CA, US
Jerry Shay - Dallas TX, US
Woodring Wright - Arlington TX, US
Elizabeth Blackburn - San Francisco CA, US
Nam Kim - Sunnyvale CA, US
Homayoun Vaziri - Toronto, CA

Board of Regents, The University of Texas System

C12Q001/68
A61K031/00
A61K045/00
A61K009/127
C12N005/08

435/006000, 424/450000, 424/093700, 514/001000, 435/372000

Method and compositions are provided for the determination of telomere length and telomerase activity, as well as the ability to increase or decrease telomerase activity in the treatment of proliferative diseases. Particularly, primers are elongated under conditions which minimize interference from other genomic sequences, so as to obtain accurate determinations of telomeric length or telomerase activity. In addition, compositions are provided for intracellular inhibition of telomerase activity and means are shown for slowing or reversing the loss of telomeric repeats in aging cells.

20070281323, Dec 6, 2007

Feb 3, 2005

10/588339

Robert Wolfert - Palo Alto CA, US
Nam Kim - Santa Clara CA, US
Xiazhu Duan - Alameda CA, US

G01N 33/573
C12Q 1/34

435007400, 435018000

This invention relates to a method for measuring enzymatically active Lipoprotein Phospholipase A2 (Lp-PLA2) in a sample. Further, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a Hybrid Immunocapture method for measuring enzymatically active Lp-PLA2 in a sample utilizing an enzymatically active Lp-PLA2 standard. In addition, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample. Specifically, this invention relates to a kit for measuring enzymatically active Lp-PLA2 in a sample containing an enzymatically active Lp-PLA2 standard.